Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$7.26 - $10.7 $23,340 - $34,400
-3,215 Reduced 0.74%
431,411 $3.23 Million
Q2 2024

Jul 29, 2024

SELL
$7.63 - $12.66 $209,092 - $346,934
-27,404 Reduced 5.93%
434,626 $3.87 Million
Q1 2024

Apr 29, 2024

SELL
$8.6 - $11.9 $392,134 - $542,604
-45,597 Reduced 8.98%
462,030 $4.68 Million
Q4 2023

Feb 07, 2024

SELL
$7.76 - $10.29 $31,544 - $41,828
-4,065 Reduced 0.79%
507,627 $5.11 Million
Q3 2023

Nov 02, 2023

BUY
$9.14 - $24.62 $363,424 - $978,940
39,762 Added 8.43%
511,692 $4.79 Million
Q2 2023

Aug 07, 2023

SELL
$23.2 - $27.29 $154,419 - $181,642
-6,656 Reduced 1.39%
471,930 $11.6 Million
Q1 2023

May 09, 2023

SELL
$22.26 - $30.85 $228,788 - $317,076
-10,278 Reduced 2.1%
478,586 $11.1 Million
Q4 2022

Feb 09, 2023

BUY
$19.96 - $28.22 $162,035 - $229,089
8,118 Added 1.69%
488,864 $12.4 Million
Q3 2022

Nov 09, 2022

BUY
$18.26 - $31.1 $160,888 - $274,022
8,811 Added 1.87%
480,746 $9.27 Million
Q2 2022

Aug 10, 2022

BUY
$19.08 - $26.7 $8.51 Million - $11.9 Million
445,904 Added 1712.97%
471,935 $12 Million
Q1 2022

May 09, 2022

BUY
$21.19 - $40.01 $3,242 - $6,121
153 Added 0.59%
26,031 $670,000
Q4 2021

Feb 09, 2022

SELL
$30.97 - $54.03 $389,045 - $678,724
-12,562 Reduced 32.68%
25,878 $1.08 Million
Q3 2021

Nov 09, 2021

SELL
$34.9 - $54.54 $39,018 - $60,975
-1,118 Reduced 2.83%
38,440 $1.67 Million
Q2 2021

Aug 10, 2021

SELL
$38.75 - $51.0 $20,925 - $27,540
-540 Reduced 1.35%
39,558 $1.87 Million
Q1 2021

May 10, 2021

BUY
$26.34 - $83.07 $7,559 - $23,841
287 Added 0.72%
40,098 $2.06 Million
Q4 2020

Feb 08, 2021

BUY
$25.51 - $43.38 $216,937 - $368,903
8,504 Added 27.16%
39,811 $1.07 Million
Q3 2020

Nov 06, 2020

SELL
$28.28 - $53.6 $2,432 - $4,609
-86 Reduced 0.27%
31,307 $1.07 Million
Q2 2020

Aug 05, 2020

BUY
$27.89 - $47.86 $875,550 - $1.5 Million
31,393 New
31,393 $1.29 Million

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $982M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.